EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models

Sakiho Ueda iD, Akira Kuzuya iD, Masayoshi Kawata iD, Kohei Okawa iD, Chika Honjo iD, Takafumi Wada iD, Mizuki Matsumoto iD, Kazuya Goto iD, Masakazu Miyamoto iD, Atsushi Yonezawa iD, Yasuto Tanabe iD, Akio Ikeda iD und 2 weitere

The FASEB Journal · 2023-11 · 37 (11)

DOI: 10.1096/fj.202300837r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 18.10.2023. Verfasst von Sakiho Ueda und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAlzheimer DiseaseMiceAnimalsReceptors, AMPAPyridonesAmyloid beta-Protein PrecursorMice, TransgenicAmyloid Precursor Protein SecretasesNitriles

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid β-proteinin vivo microdialysisperampanelβ-Cleavage of APP

Substanzen

Amyloid beta-PeptidesReceptors, AMPAPyridonesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesperampanelNitriles

Autor:innen und Institutionen

  • Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Department of Regulation of Neurocognitive Disorders, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Epilepsy, Movement Disorders and Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • School of Human Health Sciences, Faculty of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Sakiho Ueda, Akira Kuzuya, Masayoshi Kawata, Kohei Okawa, Chika Honjo, Takafumi Wada, Mizuki Matsumoto, Kazuya Goto, Masakazu Miyamoto, Atsushi Yonezawa, Yasuto Tanabe, Akio Ikeda, Ayae Kinoshita, Ryosuke Takahashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Ueda, S., Kuzuya, A., Kawata, M., Okawa, K., Honjo, C., Wada, T., Matsumoto, M., Goto, K., Miyamoto, M., Yonezawa, A., Tanabe, Y., Ikeda, A., Kinoshita, A., & Takahashi, R. (2023). Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models. The FASEB Journal, 37(11). https://doi.org/10.1096/fj.202300837r

Vancouver

Ueda S, Kuzuya A, Kawata M, Okawa K, Honjo C, Wada T, et al. Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models. The FASEB Journal. 2023;37(11). doi:10.1096/fj.202300837r

BibTeX
@article{Ueda2023,
  author = {Ueda, Sakiho and Kuzuya, Akira and Kawata, Masayoshi and Okawa, Kohei and Honjo, Chika and Wada, Takafumi and Matsumoto, Mizuki and Goto, Kazuya and Miyamoto, Masakazu and Yonezawa, Atsushi and Tanabe, Yasuto and Ikeda, Akio and Kinoshita, Ayae and Takahashi, Ryosuke},
  title = {Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models},
  journal = {The FASEB Journal},
  year = {2023},
  volume = {37},
  number = {11},
  doi = {10.1096/fj.202300837r}
}
Kostenlos starten →